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Background: There is a 3-fold risk of developing end stage kidney disease in Non-Hispanic 
African Americans compared to Non-Hispanic White Americans (Centers for Disease Control 
and Prevention, 2017). Estimated glomerular filtration rate (eGFR), one of the fundamental 
algorithms for coordinating treatment for kidney disease which factors in age, race, gender, and 
levels of creatinine, may pose an issue in this vulnerable population. Currently African 
Americans receive a correction factor between 1.21 and 1.16 to their eGFR to adjusting the value 
higher, potentially impacting appropriate kidney disease classification, and delaying beneficial 
interventions (National Kidney Foundation, 2020).  
Methods: A systematic literature search of four databases was completed.  Eligibility criteria 
included 1) published in a peer reviewed journal, 2) English language, 3) the use of race 
correction in calculating eGFR, and 4) a quantitative study design.  A total of 47 articles were 
screened with 17 selected for final review. The Johns-Hopkins Nursing Evidence - Based 
Practice evidence guide was then used to rate the strength and quality of the evidence. 
Results: Early evidence of the unreliability of race based eGFR equations emerged in 2008, and 
the body of evidence continues to grow. Recent studies have found eGFR calculated with no race 
corrections correlate best with directly measured iothalmate GFR in black patients (Zelnick et 
al., 2021), and that a potential 1,066,026 Black Americans may be reclassified to a more severe 
stage of CKD (Bragg-Gresham et al., 2021). Use of the race correction in GFR equations has 
been poorly supported in studies conducted in Africa and Brazil. For those with HIV, an accurate 
eGFR is doubly important yet all eGFR equations have marked variability. Some medical 
 iii 
facilities have successfully updated to calculating eGFR without the racial coefficient (Shi et al., 
2021). 
Conclusion: Nurses should be aware of the implications of using race correction in eGFR 
equations, educate their patients on its use, and advocate for those near threshold targets to 


































To my grandma, who fought for justice in the 1960’s protesting segregation and continued to 






















 TABLE OF CONTENTS 
INTRODUCTION ........................................................................................................................... 1 
PROBLEM ...................................................................................................................................... 5 
PURPOSE ....................................................................................................................................... 6 
METHODS ...................................................................................................................................... 7 
LIST OF FIGURES ......................................................................................................................... 8 
RESULTS ........................................................................................................................................ 9 
DISCUSSION ................................................................................................................................ 10 
LIMITATIONS............................................................................................................................... 15 
CONCLUSION .............................................................................................................................. 16 
APPENDIX A: GFR EQUATION TABLE .................................................................................... 18 
APPENDIX B: JOHN HOPKINS NURSING EVIDENCE-BASED RESEARCH EVIDENCE 
APPRAISAL .................................................................................................................................. 20 
APPENDIX C: TABLE OF EVIDENCE ....................................................................................... 24 












 The Black Lives Matter movement has inspired social and criminal justice reform 
nationwide against lingering discriminatory practices in America. It is long overdue that these 
reformations extend to healthcare, as researchers and healthcare workers have a duty to face and 
fix systemic racial inequalities in medicine. There are numerous examples of racial health 
disparities in the United States. The Coronavirus pandemic has made this glaringly evident, with 
people of color experiencing disproportionately higher rates of infection, morbidity, and 
mortality (Kullar et al., 2020). In the U.S., a country with one of the highest maternal mortality 
rates, non-Hispanic black women have a 3.2 times higher pregnancy-related mortality rate as 
compared to White women (Ahn et al., 2020; Petersen et al., 2019). Healthcare professionals 
have a moral responsibility to acknowledge and address these disparities in order to minimize 
them and promote equitable, quality outcomes for all patients.  
 In addition to these health disparities, the Center for Disease Control (CDC) (2017) 
reports that African Americans are 3 times more likely than Caucasians to develop end-stage 
kidney disease (ESKD), formerly called end-stage renal disease. The cause for this inequality is 
multifaceted and includes both biologic and social elements (Norton et al., 2016). Genetic 
screening has identified variations at the apolipoprotein L1 gene (APOL1) as a possible genetic 
component. The mechanism of action between the APOL1 variant and kidney damage remains 
unclear. Some researchers report that this genetic variance may account for 70% of the racial 
disparity, while Umeukeje & Young (2019) feel that this statistic is premature. The presence of 
two APOL1 high-risk variants alone does not cause kidney disease; it is likely that other genetic 
and environmental factors modify the expression of this gene to eventually cause kidney damage 
(Friedman & Pollak, 2011). Interestingly, the frequency of APOL1 alleles is essentially 
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nonexistent in Ethiopia, thus Americans of Ethiopian descent are not expected to be at high risk 
for kidney disease, despite being categorized as African American (Friedman & Pollak, 2011).  
Other contributors to this disparity include social conditions such as culture and poverty, 
institutional context such as healthcare and legal systems, and individual risk factors such as 
tobacco and alcohol use (Umeukeje & Young, 2019). African Americans are also more likely to 
have hypertension and diabetes, two major biologic risk factors for developing kidney disease 
(CDC, 2017). Underlying social conditions play a big role in this disparity as African Americans 
are a disadvantaged group and face contributing issues such as decreased access to healthcare, 
psychosocial and socioeconomic disadvantages, and racial biases (Norton et al., 2016). 
When analyzing racial disparities in kidney disease, it is important to look at the use of 
race-based algorithms in diagnosis and treatment (see Appendix A). Estimated glomerular 
filtration rate (eGFR) is a laboratory test commonly used to measure kidney function based on 
creatinine. Practitioners use this value for diagnosing kidney disease, staging the severity, and 
determining treatment options. A higher eGFR value indicates better kidney function. An eGFR 
considered ‘normal’ for an average healthy person is a value of 90 or higher. A value between 60 
and 90 for longer than three months may indicate kidney damage, and a value below 60 for 
longer than 3 months indicates chronic kidney disease (CKD) (National Kidney Foundation 
[NKF], 2020). CKD may progress to ESKD, which will require dialysis or transplantation for 
treatment (CDC, 2020).  
Since the mid 1920’s creatinine has been used to quantify kidney function, however, 
obtaining direct measurements of creatine clearance remains burdensome. Creatinine equations 
and assays have been developed to estimate GFR. The Cockcroft-Gault equation was developed 
in the 1970’s to estimate kidney function without a lengthy 24-hour urine collection and 
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introduced variables for weight and sex. Women received a correction factor of 15% that laid the 
groundwork for later race correction factors (Braun et al., 2021). A correction factor is a 
mathematical adjustment to a calculation to account for deviations in the sample or correct 
systematic error (Farrance & Frenkel, 2012). The Cockcroft-Gault formula is no longer 
recommended for clinical use as it gives inaccurate results, and overestimates kidney function by 
10-20% (NKF, 2021). In the late 1990’s the Modification of Diet in Renal Disease (MDRD) 
equation replaced the Cockcroft-Gault (Braun et al., 2021). The four variables the MDRD 
equationconsiders are age, sex, race, and diabetes (Florkowski et al., 2011). The developers of 
the equation found black race to be an independent predictor of kidney function, and suggested 
the difference was due to racial differences in muscle mass (Levey et al., 1999). However, only 
outdated research from 10-20 years prior on racial differences in muscle mass were cited in this 
study, and no mention of other factors such as socioeconomic class were considered. 
Additionally, the authors used a wide array of measurements of muscle mass and did not offer a 
definition of black or white (Braun et al., 2021). The MDRD equation ultimately derived a race 
correction of 1.21 for Black patients (Levey et al., 1999).  Because the MDRD sampled only 
those with kidney disease, the equation has been found to be inaccurate at better levels of kidney 
function and near the CKD threshold of 60 1mL/min/1.73 m2 (Stevens et al., 2011), still, more 
than 65% of North American laboratories continue to use this equation (Miller & Vassalotti 
2020). In 2009 the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) was 
developed to account for the shortcomings of the MDRD and is recommended for clinical use 
today (NKF, 2021). The CKD-EPI equation reduced the race correction for Blacks from 1.21 to 
1.16 and incorporates variables for age and gender (Florkowski et al., 2011).  Race, in both the 
MDRD and CKD-EPI algorithm is divided into only two categories: African American or Non-
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African American (NKF, 2020). Today, the justification for this correction factor remains as 
“higher average muscle mass and creatinine generation rate in African Americans” (NKF, 2020, 
p.6). Not only does this justification of increased muscle mass have roots in racism, this 
correlation has also been poorly supported in the literature (Braun et al., 2021).  
The ramifications of incorrectly increasing eGFR in a population that disproportionately 
suffers from kidney disease are severe, potentially delaying earlier, disease appropriate therapies 
and pre-emptive transplantation. On the other hand, waiving the correction factor, if correct, has 
the potential to over treat patients, or give them medications at a level that is too high for their 
kidneys to filter (Hornum & Feldt-Rasmussen, 2017). The use of race has been called into 
question for other medical algorithms as well (Vyas et al., 2020). Sociologists argue that race is a 
social, and not a biological construct (Williams & Sternthal, 2010). African Americans are not a 
homogenous group; they have complex ancestry and diverse genetics (Norton et al., 2016). 
Grouping such solely as “African American” may be insufficient to describe a population 
(Friedman & Pollak, 2011). Some hospitals, such as Beth Israel Deaconess Medical Center, 
Mass General Brigham and the University of Washington, have abandoned the use of race 
correction factor in eGFR in light of research highlighting the problematic nature of this 
algorithm (Gaffney, 2020). Additional research is needed to investigate the validity of current 
practices and evaluate the quality of research behind the recommendations for and against the 
use of race in calculating eGFR.   
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PROBLEM 
 Racial health disparities persist around the world. A serious commitment amongst 
researchers and medical professionals to minimize these disparities and ensure equitable 
outcomes is warranted. One example of a racial health disparity is the 3-fold risk of developing 
end stage kidney disease in Non-Hispanic African Americans compared to Non-Hispanic White 
Americans (Centers for Disease Control and Prevention, 2017). Estimated glomerular filtration 
rate (eGFR), one of the fundamental algorithms for coordinating treatment for kidney disease 
which factors in age, race, gender, and levels of creatinine, may pose an issue in this vulnerable 
population. African Americans receive a correction factor between 1.21 and 1.16 to their eGFR 
based on creatinine levels, adjusting the value higher in a population that disproportionately 
suffers from end – stage kidney disease (ESKD) (NKF, 2020). The ongoing debate over the use 
of race in calculating eGFR warrants further examination to inform professional nursing practice, 
especially nephrology nursing practice, a specialty with no currently published literature 
addressing this issue. Ignoring this issue has the potential to delay appropriate treatment and 








 The purpose of this project is to systematically appraise the quality of research that 
argues for or against the use of the eGFR correction factor and integrate findings into a cohesive 
literature review. Despite growing conversations in the medical community, there is currently no 
published literature on this debate within the discipline of nursing. As the most trusted profession 
(Saad, 2020), nurses have a duty to be aware of health disparities and advocate for their patients. 
This literature review will educate nurses on the implications of incorporating race into 
estimating kidney function and how it may exacerbate racial kidney disease disparities. 
Additionally, this review may potentially spark conversations about other areas of nursing 















 The literature review was conducted over 4 databases including PUBMED, CINAHL, 
JSTOR, and Cochrane Library. The following search terms were used to identify relevant 
articles: 
• eGFR or 'estimated GFR' or 'glomerular filtration rate' 
• AND African American or black American or black 
• AND 'race coefficient' or 'race multiplier' or 'race correction' 
After duplicates were removed from the results, each article was screened for eligibility by 
reviewing the abstract. Eligibility criteria include (1) published in a peer reviewed journal (2) 
English language (3) included use of the African American race correction in calculating eGFR 
and (4) quantitative research methods. Articles that met inclusion criteria received a full text 
review and appraisal. The articles selected for final review were appraised for the strength (Level 
I-V) and quality of evidence (A, B, C) using the Johns-Hopkins Nursing Evidence-Based 
Practice evidence level and quality guide (see Appendix B)  (Dang & Dearholt, 2017). Seventeen 
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Of the 24 relevant articles, 17 met criteria for final synthesis. Selected studies all 
employed quantitative methods using a variety of designs, including validation studies, cross-
sectional studies of existing de-identified data, retrospective studies, and prospective cohort 
studies.  All were graded as evidence Level III per the Johns Hopkins Evidence-Based Nursing 
Model. Quality ratings ranged from A-C. The largest sample size was 786,718 and the smallest 
was 64. Countries involved in studies included USA, Brazil. Nigeria, Kenya, and Thailand. The 












 While the argument against race based GFR has recently gained more traction (Gaffney, 
2020), studies published as early as 2008 raised concerns about eGFR limitations and variability. 
In an early study conducted in the Department of Defense medical system, eGFR was calculated 
using the MDRD equation to explore the association between race and compliance with selected 
CKD quality outcome targets and determine if equitable care was achieved in a system without 
financial barriers. However, in this medical system a race correction factor was not automatically 
incorporated, and providers were reminded by a message box to manually multiply the result by 
a factor of 1.18. Provider adherence to this step was not assessed. While this study found that 
Black and White patients with CKD stage 3 and 4 met most compliance targets similarly, there 
was a potential confounding variable if providers were not uniformly applying the race 
correction to Black patients. This study demonstrated that equitable access to healthcare may 
overcome CKD disparities; it also presents an example of confounding research results when 
eGFR corrections are not applied in a standardized manner. Additionally, the authors bring up 
concerns about limitations of the MDRD acknowledging the complexity of race as a construct 
that frequently exceeds the boundaries of the dichotomous race category (Black; yes/no) used in 
the MDRD equation (Gao et al., 2008). Kramer et al. (2008) found that three eGFR equations - 
the MDRD, Cystatin-C with no gender or race correction, and Cystatin-C with gender and race 
correction all had significant variability when estimating CKD prevalence across racial and 
ethnic groups, especially in women, and suggested more research into the accuracy of eGFR 
equations was needed. Two years later Peralta et al. (2010) found that the MDRD and CKD-EPI 
equations with race corrections “may lead to a systematic misclassification of CKD in young 
blacks” (p. 3938), as Black men with a GFR above the CKD threshold still had a 2.5-fold higher 
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prevalence of CKD risk factors when compared to Whites, and thus were likely being 
misclassified as CKD free.  
 Evidence against eGFR race correction factors continued to emerge. An analysis of 1342 
patients with CKD found no significant difference in the creatinine clearance to GFR ratio 
among different races or ethnicities (Lin et al., 2013). In an analysis of the CKD-EPI equation 
with and without race correction, CKD-EPI with the race correction overestimated iGFR by 
3.1mL/min/1.73 m2 (95% CI, 2.2-3.9 mL/min/1.73 m2; P < .001), while omitting the race 
correction underestimated iGFR by a smaller magnitude. Additionally, for Black participants, the 
equation with the strongest correlation with iGFR was the CKD-EPI equation without race 
correction (r=0.75) (Zelnick et al., 2021). After investigating a proposed four level CKD-EPI 
equation (Black, Asian, Native American and Hispanic, and White) to replace the standard two-
level variable (Black, White and other) race correction, Stevens et al. (2011) did not recommend 
the four-level equation, as it was more accurate in some, but not all populations. They found that 
the two-level CKD-EPI equation performed well for Blacks in the USA and Europe with a GFR 
< 90mL/min per 1.73m2, but poorly in the South African cohort, where eGFR performance was 
best with no race correction at all. These findings were converse to the study by Omuse et al. 
(2017) who studied subjectively healthy Black Africans. In their comparison of several equations 
for estimating GFR, including full age spectrum, Cockroft-Gault, and CDK-EPI and MDRD with 
and without the race corrections, CDK-EPI with the race correction ultimately performed the best 
as it accurately classified 93.6% of its healthy participants in a GFR as stage 1 CKD. However, 
Omuse et al. (2017) had no direct GFR measurement for comparison nor were urine samples for 
hematuria or proteinuria collected.  
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 Discourse and disagreement on the accuracy of eGFR equations has been found to be 
global problem amongst multiple ethnicities. In Brazil, two validation studies (Veronese et al., 
2014; Zanocco et al., 2012) failed to show an improvement in accuracy with the use of race 
correction in the CKD-EPI equation, thus Barreto et al. (2016) did not use race correction in their 
estimation of prevalence and disparity in CKD in Brazil. Haas Pizarro et al. (2020) found that 
when recalculating eGFR using the CKD-EPI equation with race correction in patients with CKD 
and a genomic ancestry > 50% African, 13 out of 23 patients were falsely reclassified to a 
normal renal function. In Asian countries, Japanese and Chinese race corrections for eGFR have 
also been derived for use in the MDRD equation. Praditpornsilpa et al. (2011) found the MDRD 
and CKD-EPI to have levels of disagreement at 9.6 mL/min per 1.73m2 and 8.0 mL/min per 
1.73m2, respectively, and recommended validation of the MDRD equation in each specific ethnic 
population.  
 Accurate measurement of GFR in patients with Human Immunodeficiency Virus (HIV) is 
essential, as this group is vulnerable to CKD and ESKD due to medication dosages of 
antiretroviral therapy (ART)being dependent on kidney function. A study of 99 HIV-infected 
and ART naïve Kenyan adults found that the CKD-EPI performed the best compared to directly 
measured iGFR (R2=23) and showed modest improvements in bias and accuracy with removal of 
race correction (85% of estimates within 30% of measured GFR) (Wyatt et al., 2013). To 
investigate this population in America, Anker et al. (2016) sampled 21,905 treatment naïve HIV-
infected Black veterans through the Department of Veterans Affairs HIV Clinical Case Registry. 
They found that those reclassified to an eGFR <60 mL/min per 1.73m2 after calculating eGFR 
without race correction had a higher incidence of CKD risk factors, when compared to Whites. 
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This finding is likely indicative of a misclassification under the MDRD formula, similar to the 
findings of Peralta et al. (2010) in healthy Black Americans.  
 The ramifications of abandoning the race correction are immense. Bragg-Gresham et al. 
(2021) estimate that removing the race correction would reclassify an estimated 1,066,027 Black 
adults in the United States, to CKD stage 3 or more severe. A study using data from two large 
medical centers found that 33.4% of their sample of 2225 would hypothetically be reclassified to 
a more severe CKD stage if the race correction was removed. Importantly, this study also found 
that none of the patients reclassified to meet the kidney transplant threshold without the race 
correction were referred, evaluated, or waitlisted for transplant (Ahmed et al., 2021). This 
coincides with a study by Zelnick et al. (2020), who found a use of eGFR with race correction 
factors was associated with a 35% (95% CI, 29%-41%) higher risk of achieving an eGFR less 
than 20 mL/min/1.73 m2 and a potential transplant delay of 1.9 years in their sample of 1658 
Black patients. Lastly, drug dosages are impacted by estimates of renal function. Two 
pharmacists found that CKD-EPI without race correction was less biased and more precise than 
CKD-EPI with race correction (median difference 4.3 [IQR = 9.8] mL/min vs 15.1 [IQR= 19.7] 
mL/min; P < 0.0001). CKD-EPI without race correction also had a higher level of agreement 
with dosing by creatinine clearance (CrCl; κ = 0.779) and was the authors ultimate 
recommendation when guiding drug dosing by creatinine clearance (Miller & Knorr, 2021).  
 Successful steps have been taken to remove race correction from GFR calculations in the 
U.S.  The University of Washington Medicine System moved from MDRD to CKD-EPI with no 
race correction on May 29th, 2020 (Hong, 2020; Shi et al., 2021). Before the switch, it was the 
providers choice whether to include a race correction. Shi et al. (2021) studied the impact of the 
change at the University of Washington Medical Center and found that the change in use from 
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the MDRD to CKD-EPI with no race correction resulted in 3.5% of all patients reclassified to a 
worse kidney function (N=241,760). They also found fewer patients overall with an eGFR <60 
















 The principal limitation in this review was the use of variable methods to validate eGFR 
equations. While some studies compared to direct measure of GFR such as iothalamate clearance 
(iGFR) (Zelnick et al., 2021; Wyatt et al., 2013), others created their own model (Anker et al., 
2016; Peralta et al., 2010), used other measurements such as urine microalbumin (Barreto et al., 
2016; Lin et al., 2013), GFR mean (Stevens et al., 2011) or had no direct measure for comparison 
(Abefe et al., 2009; Bragg-Gresham et al., 2021; Haas Pizarro et al., 2020; Kramer et al., 2008; 
Omuse et al., 2017) The second limitation was the complexity of statistical analyses performed 
in each of the studies. As a novice researcher, the depth of the review was based on the author’s 

























 Substantial evidence against the need for race correction of eGFR equations continues to 
emerge in the literature. Some facilities in the U.S. have already started to move away from race 
- based MDRD and CKD-EPI equations (Gaffney, 2020; Shi et al., 2021). Both early and recent 
research has identified inaccuracies in eGFR equations. Additionally, the race correction has 
been poorly validated for accuracy in other countries, including Brazil (Barreto et al., 2016; Haas 
Pizarro et al., 2020) and South Africa (Stevens et al., 2011). For patients with HIV, accurate 
classification of kidney function is key to dosing of medications necessary for their survival, yet 
Blacks with HIV are likely overestimated in their kidney function (Anker et al., 2016; Wyatt et 
al., 2013). To guide drug dosages, CKD-EPI without race correction performed the best (Miller 
& Knorr, 2021).  
 In addition to the quantitative research, sociologic arguments have emerged. Braun et al. 
(2021) found that in a literature review of research on GFR comparisons between Black and 
White persons with CKD, the majority (28 out of 38) offer no explanation for the racial 
difference demonstrating that muscle mass as an innate difference has become a “fact” with no 
need for explicit restating. Eneanya et al. (2019) explained that using race for clinical decision 
making “is justified only if (1) the use confers substantial benefit; (2) the benefit cannot be 
achieved through other feasible approaches; (3) patients who reject race categorization are 
accommodated fairly; and (4) the use of race is transparent” (p. 114). In response to these 
criteria, Levey et al. (2020) propose continuation of the use of race correction with full 
disclosure to patients, and mindful use of Cystatin-C as a confirmatory test.  
 The implications of these findings for professional nursing practice warrant education 
and advocacy. An understanding of culture, socioeconomic factors, and the consequences of 
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treating racial groups as a homogenous population is paramount to combatting disparities 
(Pearson, 2008). Nephrology nurses especially should be aware of the racial disparities in CKD 
and how current eGFR race corrections may exacerbate them. Black patients with poor kidney 
function and patients with HIV are especially vulnerable populations for overestimating kidney 
function. Nephrology nurses should take notice of patients who are near thresholds such as 
below 60 mL/min per 1.73m2 for diagnosis of CKD or near 20 mL/min per 1.73m2 for transplant 
qualification, and advocate for other confirmatory diagnostic tests. Nurses may also wish to 
inform patients if the correction is being used and educate them on its purpose and implications 
to increase transparency and meet the criteria proposed by Eneanya et al. (2019). Lastly, 
depending upon the eGFR equation being used, there is potential for under or overestimating 
drug dosages; nurses should vigilant to monitor for adverse effects from medication.  
 More research on this topic is warranted as the methods used to validate and compare 
eGFR equations varied across studies. In addition, confirmatory studies on drug dosages, using 
consistent measures of GFR for comparison and conducted in a variety of populations are 
needed. The National Kidney Foundation – American Society of Nephrology task force is 
actively working to determine and approach to address this issue and construct recommendations 



















































4 Variable MDRD: 
 
186 x [Plasma Creatinine (μmol/L) x 0.0011312] -1.154 x [age (years)] -0.203 x [0.742 if female] x 






Female with Creatinine < 62 μmol/L; use eGFR = 144 x (Cr/61.6)-0.329 x (0.993)Age  
 
Female with Creatinine > 62 μmol/L; use eGFR = 144 x (Cr/61.6)-1.209 x (0.993)Age  
 
Male with Creatinine < 80 μmol/L; use eGFR = 141 x (Cr/79.2)-0.411 x (0.993)Age  
 






























































Evidence and Quality Rating adapted from Dang & Dearholt (2017) 
Evidence Levels Quality Ratings 
Level I 
   Experimental study, randomized 
controlled trial (RCT) 
   Explanatory mixed method 
design that includes only a level I 
quaNtitative study 
   Systematic review of RCTs, with or 
without meta- analysis 
QuaNtitative Studies 
A High quality: Consistent, generalizable results; sufficient sample size 
for the study design; adequate control; definitive conclusions; consistent 
recommendations based on comprehensive literature review that includes 
thorough reference to scientific evidence. 
B Good quality: Reasonably consistent results; sufficient sample size 
for the study design; some control, fairly definitive conclusions; 
reasonably consistent recommendations based on fairly comprehensive 
literature review that includes some reference to scientific evidence. 
C Low quality or major flaws: Little evidence with inconsistent 
results; insufficient sample size for the study design; conclusions 
cannot be drawn. 
QuaLitative Studies 
No commonly agreed-on principles exist for judging the quality of 
quaLitative studies. It is a subjective process based on the extent to which 
study data contributes to synthesis and how much information is known 
about the researchers’ efforts to meet the appraisal criteria. 
For meta-synthesis, there is preliminary agreement that quality 
assessments of individual studies should be made before synthesis to 
screen out poor-quality studies1. 
A/B High/Good quality is used for single studies and meta-syntheses2. 
The report discusses efforts to enhance or evaluate the quality of 
the data and the overall inquiry in sufficient detail; and it 
describes the specific techniques used to enhance the quality of 
the inquiry. Evidence of some or all of the following is found in 
the report: 
• Transparency: Describes how information was documented 
to justify decisions, how data were reviewed by others, and 
how themes and categories were formulated. 
• Diligence: Reads and rereads data to check interpretations; 
seeks opportunity to find multiple sources to corroborate 
evidence. 
• Verification: The process of checking, confirming, and ensuring 
methodologic coherence. 
• Self-reflection and scrutiny: Being continuously 
aware of how a researcher’s experiences, background, 
or prejudices might shape and bias analysis and 
interpretations. 
• Participant-driven inquiry: Participants shape the scope and 
breadth of questions; analysis and interpretation give voice 
to those who participated. 
• Insightful interpretation: Data and knowledge are linked in 
meaningful ways to relevant literature. 
C Low quality studies contribute little to the overall review of findings 
and have few, if any, of the features listed for high/good quality. 
Level II 
Quasi-experimental study 
   Explanatory mixed method 
design that includes only a level II 
quaNtitative study 
   
   Systematic review of a combination 
of RCTs and quasi-experimental 
studies, or quasi- experimental 




  Systematic review of a combination 
of RCTs, quasi-experimental and   
nonexperimental studies, or 
nonexperimental studies only, with 
or without meta-analysis 
   
Exploratory, convergent, or 
multiphasic mixed methods 
studies 
   
Explanatory mixed method design 
that includes only a level III 
quaNtitative study 
 
QuaLitative study Meta-synthesis 
 22 
 
Evidence Levels Quality Ratings 
Level IV 
Opinion of respected 
authorities and/or nationally 
recognized expert 
committees or consensus 
panels based on scientific 
evidence 
Includes: 
• Clinical practice guidelines 
• Consensus panels/position 
statements 
A High quality: Material officially sponsored by a professional, public, or 
private organization or a government agency; documentation of a 
systematic literature search strategy; consistent results with sufficient 
numbers of well-designed studies; criteria-based evaluation of overall 
scientific strength and quality of included studies and definitive 
conclusions; national expertise clearly evident; developed or revised 
within the past five years 
B Good quality: Material officially sponsored by a professional, public, or 
private organization or a government agency; reasonably thorough and 
appropriate systematic literature search strategy; reasonably consistent 
results, sufficient numbers of well-designed studies; evaluation of 
strengths and limitations of included studies with fairly definitive 
conclusions; national expertise clearly evident; developed or revised 
within the past five years 
C Low quality or major flaws: Material not sponsored by an official 
organization or agency; undefined, poorly defined, or limited literature 
search strategy; no evaluation of strengths and limitations of included 
studies, insufficient evidence with inconsistent results, conclusions cannot 
be drawn; not revised within the past five years 
 
Level V 
Based on experiential and 
nonresearch evidence Includes: 
• Integrative reviews 
• Literature reviews 
• Quality improvement, 
program, or financial 
evaluation 
• Case reports 
• Opinion of nationally 
recognized expert(s) 
based on experiential 
evidence 
Organizational Experience (quality improvement, program or 
financial evaluation) 
A High quality: Clear aims and objectives; consistent results 
across multiple settings; formal quality improvement, 
financial, or program evaluation methods used; definitive 
conclusions; consistent recommendations with thorough 
reference to scientific evidence 
B Good quality: Clear aims and objectives; consistent results in a single 
setting; formal quality improvement, financial, or program evaluation 
methods used; reasonably consistent recommendations with some 
reference to scientific evidence 
C Low quality or major flaws: Unclear or missing aims and objectives; 
inconsistent results; poorly defined quality improvement, financial, or 
program evaluation methods; recommendations cannot be made 
 
Integrative Review, Literature Review, Expert Opinion, Case 
Report, Community Standard, Clinician Experience, Consumer 
Preference 
A High quality: Expertise is clearly evident; draws definitive 
conclusions; provides scientific rationale; thought leader(s) in the field 
B Good quality: Expertise appears to be credible; draws fairly definitive 
conclusions; provides logical argument for opinions 
C Low quality or major flaws: Expertise is not discernable or is dubious; 

































Design Sample / 
Settings 
Aim / Objective eGFR  
Equation(s) 












Nigerians and 34 
Nigerian patients 




passing at least 




To examine the 
usefulness of 6 
eGFR formulas 












All predictive formulas 
correlated significantly 
with creatinine clearance 




outperformed MDRD and 
had the least variance 
(6.3% vs. 16.3%) and 
highest accuracy (49.3% 
vs 9.9%) 
 
Cockroft-Gault had the 
highest r2 of 0.94 
Cockroft-























primary care and 
specialty 
practices. 
To examine the 
impact of the 
race multiplier 
for African 












743 of 2225 African 
American patients would 
be reclassified to a more 
severe CKD stage with no 
race correction 
 
64 of 2069 African 
American patients would 
be reassigned  
To meet transplant 
requirements with no race 
multiplier, yet 0 of these 
64 were referred, 
evaluated, or waitlisted 




















Design Sample / Settings Aim / Objective eGFR  
Equation(s) 













veterans in the 


































CKD is strongly 
associated with 











Persons with eGFR 
<45 mL/min/1.73m2 
had a higher risk of 
death compared with 
those with eGFR >80 
mL/min/1.73m2 
among both Blacks  
and Whites, but the 
association 
appeared to be 
stronger in Blacks.  
 
Blacks with eGFR 45-
60 mL/min/1.73m2 
also had a higher risk 
of death but 





attenuated when eGFR 
was re-calculated 




may be more 
appropriate for 









Design Sample / Settings Aim / Objective eGFR 
Equation(s) 

















enrolled in the 
Brazilian 
Longitudinal 







CKD in Brazil 
 
Measured eGFR 










creatinine ratio (ACR) 
or low eGFR was 
higher in individuals 
of low socioeconomic 





in the increases in 
reduced eGFR and 
high ACRs with age 
and race.   
 
The combination of 
higher prevalence of 
CKD in black and 
indigenous individuals 
could not be explained 
by socioeconomic and 
health risk factors. 
Differences most 
likely explained by 



























Design Sample / Settings Aim / Objective eGFR 
Equation(s) 



















N = 9682 self-
reported Black 

















eGFR of 60 
mL/min/1.73 m2  
both the US 
general 
population and 
the population of 
US veterans who 
use the Veterans 
Affairs (VA) 
Health System. 






The mean eGFR 
decreased from 102.8 
mL/min/1.73m2 to 
88.1 mL/min/1.73m2 
using the CKD-EPI 
equation without the 
race coefficient in the 
US adult black 
population. 
 
The mean eGFR 
decreased from 82.9 
mL/min/1.73 m2  to 
71.6 mL/min/1.73 m2 
without the race 
coefficient in black 
US veterans. 
 
Elimination of the race 
coefficient would 
result in 981,038 more 
Black adults in the 
US, and an additional 
84,988 Black adults in 
the VA health system 









elimination of the 









Design Sample / Settings Aim / Objective eGFR 
Equation(s) 




























CKD stage 3 or 
stage 4 who 
receive free 
medical care as 
beneficiaries of 
the Department of 
Defense medical 
system 
Determine if care 
is equitable 
between Blacks 
and Whites with 


















monitoring was the 
only significant 
difference between 
White and Black 
 






with CKD stage 3 
and 4 targets was not 
significantly lower 
for Blacks that 
Whites with the 
exception of LDL. 
 
Patients categorized 
as “other” race were 
less likely to achieve 























Blacks, both in 
comparison to 

















Design Sample / Settings Aim / Objective eGFR 
Equation(s) 





















Cohort all had 
type 1 diabetes  
 
CKD defined as 
eGRF , 60ml/min. 
To compare, in 
patients with 
type 1 diabetes, 
the eGFR 
calculated without 
the use of the 
correction factor, 
with the values 
obtained using 
the correction 
factor in patients 
presenting 50% or 
more of African 
genomic ancestry. 





CKD was present in 
23 patients and 
56.5% of them were 
redefined as having 
normal renal function 




did not match self-
reported race 
Genomic ancestry 



























Design Sample / 
Settings 
















cohort, but who 
















4 variable MDRD 
 
Cystatin C with / 








were more congruent 
with the use of 
Cystatin C-based 
equation without the 
use of coefficients. 
 
Men:  CKD 
prevalence estimates 
differed significantly 
with the Cystatin C 
formula which 
incorporates gender 





estimates vary across 
racial/ethnic groups, 
and the degree of 
variability depends 
on the 



























Design Sample / 
Settings 


































higher, and being 
non-Hispanic 
Black with lower, 
CrCl/GFR ratio. 





No indication of 
differences between 
Black and Whites in 






















N = 210 
n = 177 Black 
patients 










ns in the 
product 
labeling. 
To determine the 
impact of 
removing the race 
coefficient on 
drug dosing in 





using Body Surface 
Area and no race 
correction 
 




18% rate of discordance 
when GFR was 
estimated with race 
coefficient vs. without.  
GFR without race had a 
higher level of 
agreement with dosing 




without Race had a 
higher level of 
agreement 
and less drug dose 
discordance than CKD-
EPI with race 
coefficients, in 



















Design Sample / 
Settings 




Omuse et al, 
(2017) 
Secondary 
analysis of data 





Subjectively    
healthy Kenyan 























risk factors for 
CKD and eGFR 
using these 
equations 
4 -v MDRD with / 






Full Age Spectrum 
 
Serum creatinine CKD-
EPI with/without race 
and gender coefficients 
 
 
 The 4v–MDRD equation 
without 
correction for race 
classified the least 
number of participants 
(61.7%) as having an 




CKD-EPI with race 
correction performed the 
best in their population, 
and MDRD performed 
the worst 
 
Only age had a 
statistically significant 
linear association with 

















































Design Sample / 
Settings 
Aim / Objective eGFR 
Equation(s) 




Peralta et al. 
(2010) 
Secondary 
analysis of data 



















Oakland, CA  
Study the 
prevalence of 
CKD in a young, 
healthy, bi-racial 
cohort using the 
MDRD 
and the CKD-EPI 
equations; and 
evaluate the 






MDRD = 1.21 
 
CKD-EPI = 1.16 
 
CARDIA derived 
race coefficient = 
1.12  
Using the MDRD 
equation, 
prevalence of CKD 
stages 4 and 5 was 
higher for Blacks 
compared with 
Whites, yet Whites 
had a higher 
prevalence of CKD 
stages 3 and above.  
 
Prevalence of CKD 
was similar for 





with close to the 
threshold of stake 3 
CKD, Blacks had 
higher incidence of 















higher rates of 
CKD stage 3, 
Blacks with 
eGFRs just above 
the CKD 
threshold had 
higher rates of  
  CKD risk factors 
 
Current equations 
used to define 
CKD may 
systematically 
  miss a high-risk 
  group of Blacks at 
a crucial time in 













Author / Year Design Sample / 
Settings 






 eGRF equation    
validation study 






EPI and MDRD 

















Derived an adjustment 
of 1.129 in MDRD 
equation for Thais 
 
MDRD had a 
disagreement with 
measured GFR of 9.6 
mL/min/1.73 m2 
 
CKD-EPI was 8.0 mL/ 
min/1.73 m2 
 
Japanese was 1.9 
mL/min/1.73 m2 
 






























































To evaluate the 







the removal of 
the race 
correction 











3.5% of all patients, 
including 4.29%  of blacks 
were reclassified to 
categorically have worse 
kidney function when 
changing from MDRD to 
CKD-EPIno race 
 
Distributions of creatinine 
and eGFR calculated with 
CKD-EPI with no race 
correction were not 





Overall number of those 
with eGFR under 
threshold for nephrology 







































Design Sample / 
Settings 





























and n=99 from 
South Africa 
Explore the 
























Black coefficient = 
1.160 
Native American 
and Hispanic = 
1.010 
Asian = 1.052 
The four-level race 
equation that was 
developed for the study 
was more accurate than the 
CKD-EPI (two-level race-
equation in some but not 
all populations. 
In South Africa, both the 
two and four level race 
equations performed 
worse, and performance 
was better when no 
coefficient was used 
Minimal bias in two-level 
race equation, except for 
Asians 
A four variable CKD-EPI 
is not accurate enough to 
be implemented in clinical 
practice. 
 
Racial differences in 
creatinine-based estimating 
equations likely reflect 
geographic and ethnic 
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Equation(s) 







compared against a 
direct measure of 




was calculated using 
dried blood spots on 
filters, an approach 
for areas with low 









eGFR has the 
lowest bias ratio 
and best accuracy 













iGFR for direct 
measurement 
CKD-EPI had the highest 
accuracy, and bias and 
accuracy were improved by 
eliminating the Black race 
coefficient 
 
The MDRD also performed 










































Design Sample / 
Settings 
Aim / Objective eGFR 
Equation(s) 



















To compare eGFR 
with measured 
GFR and evaluate 
the association 
between eGFR 
calculated with vs 
without a 
coefficient for race 











does not have a 
race coefficient 
 
iGFR for direct 
measurement 
The CKD-EPI eGFR with 
the race 
coefficient overestimated 
iGFR by a mean of 3.1 
mL/min/1.73 m2 and by 
5.1mL/min/1.73m2 at 
lower GFR levels 
 
The mean difference 
between CKD-EPI eGFR 
without the race 
coefficient and iGFR was 
much smaller at -
1.71mL/min/1.73m2 
  Use of eGFR race  
  coefficient had a 35%  
higher risk of achieving an 
eGFR less than 20 
mL/min/1.73 m2 and a 
shorter median time 
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